pmc logo image
Logo of postmedjPostgraduate Medical JournalCurrent TOCInstructions for authors
Journal List > Postgrad Med J > v.63(739); May 1987

Formats:
Postgrad Med J. 1987 May; 63(739): 337–343.
PMCID: PMC2428476
Copyright notice
Critical review of clinical trials in senile dementia--II.
J. M. Orgogozo and R. Spiegel
Neurological Department, University of Bordeaux II Pellegrin Hospital, France.
Small right arrow pointing to: This article has been cited by other articles in PMC.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 337
337
icon of scanned page 338
338
icon of scanned page 339
339
icon of scanned page 340
340
icon of scanned page 341
341
icon of scanned page 342
342
icon of scanned page 343
343
 
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 Jul;34(7):939–944. [PubMed]
  • Yesavage JA, Tinklenberg JR, Hollister LE, Berger PA. Vasodilators in senile dementias: a review of the literature. Arch Gen Psychiatry. 1979 Feb;36(2):220–223. [PubMed]
  • Wittenborn JR. Pharmacotherapy for age-related behavioral deficiencies. J Nerv Ment Dis. 1981 Mar;169(3):139–156. [PubMed]
  • Goodnick P, Gershon S. Chemotherapy of cognitive disorders in geriatric subjects. J Clin Psychiatry. 1984 May;45(5):196–209. [PubMed]
  • Prien RF. Chemotherapy in chronic organic brain syndrome--a review of the literature. Psychopharmacol Bull. 1973 Oct;9(4):5–20. [PubMed]
  • Hollister LE. Drugs for mental disorders of old age. JAMA. 1975 Oct 13;234(2):195–198. [PubMed]
  • Gaitz CM, Varner RV, Overall JE. Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo. Arch Gen Psychiatry. 1977 Jul;34(7):839–845. [PubMed]
  • Reisberg B, Ferris SH, Gershon S. An overview of pharmacologic treatment of cognitive decline in the aged. Am J Psychiatry. 1981 May;138(5):593–600. [PubMed]
  • Cook P, James I. Cerebral vasodilators (second of two parts). N Engl J Med. 1981 Dec 24;305(26):1560–1564. [PubMed]
  • Rao DB, Georgiev EL, Paul PD, Guzman AB. Cyclandelate in the treatment of senile mental changes: a double-blind evaluation. J Am Geriatr Soc. 1977 Dec;25(12):548–551. [PubMed]
  • Capote B, Parikh N. Cyclandelate in the treatment of senility: a controlled study. J Am Geriatr Soc. 1978 Aug;26(8):360–362. [PubMed]
  • Cox JR. Double-blind evaluation of naftidrofuryl in treating elderly confused hospitalised patients. Gerontol Clin (Basel). 1975;17(3):160–167. [PubMed]
  • Branconnier RJ, Cole JO. The impairment index as a symptom-independent parameter of drug efficacy in geriatric psychopharmacology. J Gerontol. 1978 Mar;33(2):217–223. [PubMed]
  • Hughes JR, Williams JG, Currier RD. An ergot alkaloid preparation (Hydergine) in the treatment of dementia: critical review of the clinical literature. J Am Geriatr Soc. 1976 Nov;24(11):490–497. [PubMed]
  • McDonald RJ. Hydergine: a review of 26 clinical studies. Pharmakopsychiatr Neuropsychopharmakol. 1979 Nov;12(6):407–422. [PubMed]
  • Rosen HJ. Mental decline in the elderly: pharmacotherapy (ergot alkaloids versus papaverine). J Am Geriatr Soc. 1975 Apr;23(4):169–174. [PubMed]
  • Shader RI, Harmatz JS, Salzman C. A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment--Geriatric (SCAG). J Am Geriatr Soc. 1974 Mar;22(3):107–113. [PubMed]
  • Venn RD. The Sandoz Clinical Assessment-Geriatric (SCAG) scale. A general-purpose psychogeriatric rating scale. Gerontology. 1983;29(3):185–198. [PubMed]
  • Kugler J, Oswald WD, Herzfeld U, Seus R, Pingel J, Welzel D. Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns. Dtsch Med Wochenschr. 1978 Mar 17;103(11):456–462. [PubMed]
  • van Loveren-Huyben CM, Engelaar HF, Hermans MB, van der Bom JA, Leering C, Munnichs JM. Double-blind clinical and psychologic study of ergoloid mesylates (Hydergine) in subjects with senile mental deterioration. J Am Geriatr Soc. 1984 Aug;32(8):584–588. [PubMed]
  • Yesavage JA, Hollister LE, Burian E. Dihydroergotoxine: 6-mg versus 3-mg dosage in the treatment of senile dementia. Preliminary report. J Am Geriatr Soc. 1979 Feb;27(2):80–82. [PubMed]
  • Hollister LE, Yesavage J. Ergoloid mesylates for senile dementias: unanswered questions. Ann Intern Med. 1984 Jun;100(6):894–898. [PubMed]
  • Subhan Z, Hindmarch I. The psychopharmacological effects of Ginkgo biloba extract in normal healthy volunteers. Int J Clin Pharmacol Res. 1984;4(2):89–93. [PubMed]
  • Branconnier RJ. The efficacy of the cerebral metabolic enhancers in the treatment of senile dementia. Psychopharmacol Bull. 1983 Spring;19(2):212–219. [PubMed]
  • Dimond SJ, Brouwers EM. Increase in the power of human memory in normal man through the use of drugs. Psychopharmacology (Berl). 1976 Sep 29;49(3):307–309. [PubMed]
  • Thompson LW, Davis GC, Obrist WD, Heyman A. Effects of hyperbaric oxygen on behavioral and physiological measures in elderly demented patients. J Gerontol. 1976 Jan;31(1):23–28. [PubMed]
  • Raskin A, Gershon S, Crook TH, Sathananthan G, Ferris S. The effects of hyperbaric and normobaric oxygen on cognitive impairment in the elderly. Arch Gen Psychiatry. 1978 Jan;35(1):50–56. [PubMed]
  • Marcer D, Hopkins SM. The differential effects of meclofenoxate on memory loss in the elderly. Age Ageing. 1977 May;6(2):123–131. [PubMed]
  • Cooper AJ, Magnus RV. A placebo-controlled study of pyritinol ('Encephabol') in dementia. Pharmatherapeutica. 1980;2(5):317–322. [PubMed]
  • Tazaki Y, Omae T, Kuromaru S, Ohtomo E, Hasegawa K, Mori A, Kurihara M, Kutsusawa N, Okada T. Clinical effect of Encephabol (pyritinol) in the treatment of cerebrovascular disorders. J Int Med Res. 1980;8(2):118–126. [PubMed]
  • Berthaux P, Laforestrie R. Mise en évidence de l'activité thérapeutique du 5023 SE sur l'efficacité intellectuelle et psycho-motrice des sujets âgés détériorés. Etude contrôlée à double-insu contre placebo. Presse Med. 1983 Mar 24;12(13):852–855. [PubMed]
  • Crook T. Central-nervous-system stimulants: appraisal of use in geropsychiatric patients. J Am Geriatr Soc. 1979 Oct;27(10):476–477. [PubMed]
  • Kaplitz SE. Withdrawn, apathetic geriatric patients responsive to methylphenidate. J Am Geriatr Soc. 1975 Jun;23(6):271–276. [PubMed]
  • Crook T, Ferris S, Sathananthan G, Raskin A, Gershon S. The effect of methylphenidate on test performance in the cognitively impaired aged. Psychopharmacology (Berl). 1977 May 9;52(3):251–255. [PubMed]
  • Harwart D. The treatment of chronic cerebrovascular insufficiency. A double-blind study with pentoxifylline ('Trental' 400). Curr Med Res Opin. 1979;6(2):73–84. [PubMed]
  • Parnetti L, Ciuffetti G, Mercuri M, Senin U. Haemorheological pattern in initial mental deterioration: results of a long-term study using piracetam and pentoxifylline. Arch Gerontol Geriatr. 1985 Jul;4(2):141–155. [PubMed]
  • Yates CM, Allison Y, Simpson J, Maloney AF, Gordon A. Dopamine in Alzheimer's disease and senile dementia. Lancet. 1979 Oct 20;2(8147):851–852. [PubMed]
  • Loranger AW, Goodell H, Lee JE, McDowell F. Levodopa treatment of Parkinson's syndrome. Improved intellectual functioning. Arch Gen Psychiatry. 1972 Feb;26(2):163–168. [PubMed]
  • Drachman DA, Stahl S. Letter: Extrapyramidal dementia and levodopa. Lancet. 1975 Apr 5;1(7910):809. [PubMed]
  • Kristensen V, Olsen M, Theilgaard A. Levodopa treatment of presenile dementia. Acta Psychiatr Scand. 1977 Jan;55(1):41–51. [PubMed]
  • Montanari C, Vallecorsi GF, Bavazzano A, D'Ayalavalva G, Sanesi P. Clinical trial with amantadine and pemoline in elderly patients. Age Ageing. 1976 Feb;5(1):6–11. [PubMed]
  • Nicrosini F, Pasotti C. Studio clinico controllato sull'attività e sulla tollerabilità del trivastan. Minerva Med. 1976 May 26;67(26):1745–1750. [PubMed]
  • Varkonyi-Wallerstein P, Licht B, Kronenwerth D. Zur Behandlung zerebraler Insuffizienzerscheinungen alter Menschen. Randomisierte Vergleichsprüfung mit Trivastal. Ther Ggw. 1976 Feb;115(2):265–280. [PubMed]
  • Scholing WE. Langzeitbehandlung des organischen Psychosyndroms. Psychometrische Untersuchungen mit Piribedil in Retardform. Ther Ggw. 1979;118(1):66–84. [PubMed]
  • Borenstein P, Soret Ch, Graille D. Contribution a lEtude des syndromes démentiels sous l'action de la bromocriptine. Sem Hop. 57(15-16):801–809. [PubMed]
  • Phuapradit P, Phillips M, Lees AJ, Stern GM. Bromocriptine in presenile dementia. Br Med J. 1978 Apr 22;1(6119):1052–1053. [PubMed]
  • Gottfries CG. Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology (Berl). 1985;86(3):245–252. [PubMed]
  • Ferris SH, Sathananthan G, Gershon S, Clark C, Moshinsky J. Cognitive effects of ACTH 4-10 in the elderly. Pharmacol Biochem Behav. 1976;5(Suppl 1):73–78. [PubMed]
  • Dornbush RL, Volavka J. ACTH 4-10: a study of toxicological and behavioral effects in an aging sample. Neuropsychobiology. 1976;2(5-6):350–360. [PubMed]
  • Branconnier RJ, Cole JO, Gardos G. ACTH 4-10 in the amelioration of neuropsychological symptomatology associated with senile organic brain syndrome. Psychopharmacology (Berl). 1979 Mar 22;61(2):161–165. [PubMed]
  • Gaillard AW, Varey CA. Some effects of an ACTH 4-9 analog (Org 2766) on human performance. Physiol Behav. 1979 Jul;23(1):79–84. [PubMed]
  • Soininen H, Koskinen T, Helkala EL, Pigache R, Riekkinen PJ. Treatment of Alzheimer's disease with a synthetic ACTH 4-9 analog. Neurology. 1985 Sep;35(9):1348–1351. [PubMed]
  • Miller LH, Harris LC, Van Riezen H, Kastin AJ. Neuroheptapeptide influence on attention and memory in man. Pharmacol Biochem Behav. 1976;5(Suppl 1):17–21. [PubMed]
  • Will JC, Abuzzahab FS, Sr, Zimmermann RL. The effects of ACTH4-10 versus placebo in the memory of symptomatic geriatric volunteers. Psychopharmacol Bull. 1978 Jan;14(1):25–27. [PubMed]
  • Gaillard AW, Varey CA. Some effects of an ACTH 4-9 analog (Org 2766) on human performance. Physiol Behav. 1979 Jul;23(1):79–84. [PubMed]
  • Legros JJ, Gilot P, Seron X, Claessens J, Adam A, Moeglen JM, Audibert A, Berchier P. Influence of vasopressin on learning and memory. Lancet. 1978 Jan 7;1(8054):41–42. [PubMed]
  • Delwaide PJ, Devoitille JM, Ylieff M. Acute effect of drugs upon memory of patients with senile dementia. Acta Psychiatr Belg. 1980 Sep–Oct;80(5):748–754. [PubMed]
  • Blake DR, Dodd MJ, Evans JG. Vasopressin in amnesia. Lancet. 1978 Mar 18;1(8064):608. [PubMed]
  • Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976 Dec 25;2(8000):1403–1403. [PubMed]
  • White P, Hiley CR, Goodhardt MJ, Carrasco LH, Keet JP, Williams IE, Bowen DM. Neocortical cholinergic neurons in elderly people. Lancet. 1977 Mar 26;1(8013):668–671. [PubMed]
  • Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci. 1977 Nov;34(2):247–265. [PubMed]
  • Perry EK, Tomlinson BE, Blessed G, Bergmann K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J. 1978 Nov 25;2(6150):1457–1459. [PubMed]
  • Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res. 1979 Aug 3;171(2):319–327. [PubMed]
  • Boyd WD, Graham-White J, Blackwood G, Glen I, McQueen J. Clinical effects of choline in Alzheimer senile dementia. Lancet. 1977 Oct 1;2(8040):711–711. [PubMed]
  • Etienne P, Gauthier S, Dastoor D, Collier B, Ratner J. Lecithin in Alzheimer's disease. Lancet. 1978 Dec 2;2(8101):1206–1206. [PubMed]
  • Signoret JL, Whiteley A, Lhermitte F. Influence of choline on amnesia in early Alzheimer's disease. Lancet. 1978 Oct 14;2(8094):837–837. [PubMed]
  • Ferris SH, Sathananthan G, Reisberg B, Gershon S. Long-term choline treatment of memory-impaired elderly patients. Science. 1979 Sep 7;205(4410):1039–1040. [PubMed]
  • Mohs RC, Davis KL, Tinklenberg JR, Hollister LE, Yesavage JA, Kopell BS. Choline chloride treatment of memory deficits in the elderly. Am J Psychiatry. 1979 Oct;136(10):1275–1277. [PubMed]
  • Smith CM, Swash M, Exton-Smith AN, Phillips MJ, Overstall PW, Piper ME, Bailey MR. Choline therapy in Alzheimer's disease. Lancet. 1978 Aug 5;2(8084):318–318. [PubMed]
  • Etienne P, Dastoor D, Gauthier S, Ludwick R, Collier B. Alzheimer disease: lack of effect of lecithin treatment for 3 months. Neurology. 1981 Dec;31(12):1552–1554. [PubMed]
  • Bartus RT, Dean RL, 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982 Jul 30;217(4558):408–414. [PubMed]
  • Renvoize EB, Jerram T. Choline in Alzheimer's disease. N Engl J Med. 1979 Aug 9;301(6):330. [PubMed]
  • Thal LJ, Rosen W, Sharpless NS, Crystal H. Choline chloride fails to improve cognition of Alzheimer's disease. Neurobiol Aging. 1981 Fall;2(3):205–208. [PubMed]
  • Brinkman SD, Pomara N, Goodnick PJ, Barnett N, Domino EF. A dose-ranging study of lecithin in the treatment of primary degenerative dementia (Alzheimer disease). J Clin Psychopharmacol. 1982 Aug;2(4):281–285. [PubMed]
  • Ferris SH, Sathananthan G, Gershon S, Clark C. Senile dementia: treatment with deanol. J Am Geriatr Soc. 1977 Jun;25(6):241–244. [PubMed]
  • Peters BH, Levin HS. Memory enhancement after physostigmine treatment in the amnesic syndrome. Arch Neurol. 1977 Apr;34(4):215–219. [PubMed]
  • Davis KL, Mohs RC. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry. 1982 Nov;139(11):1421–1424. [PubMed]
  • Beller SA, Overall JE, Swann AC. Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level. Psychopharmacology (Berl). 1985;87(2):147–151. [PubMed]
  • Peters BH, Levin HS. Effects of physostigmine and lecithin on memory in Alzheimer disease. Ann Neurol. 1979 Sep;6(3):219–221. [PubMed]
  • Thal LJ, Fuld PA, Masur DM, Sharpless NS. Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol. 1983 May;13(5):491–496. [PubMed]
  • Mohs RC, Davis BM, Greenwald BS, Mathé AA, Johns CA, Horvath TB, Davis KL. Clinical studies of the cholinergic deficit in Alzheimer's disease. II. Psychopharmacologic studies. J Am Geriatr Soc. 1985 Nov;33(11):749–757. [PubMed]
  • Summers WK, Viesselman JO, Marsh GM, Candelora K. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol Psychiatry. 1981 Feb;16(2):145–153. [PubMed]
  • Christie JE, Shering A, Ferguson J, Glen AI. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry. 1981 Jan;138:46–50. [PubMed]
  • Wesseling H, Agoston S, Van Dam GB, Pasma J, DeWit DJ, Havinga H. Effects of 4-aminopyridine in elderly patients with Alzheimer's disease. N Engl J Med. 1984 Apr 12;310(15):988–989. [PubMed]
  • Wettstein A, Spiegel R. Clinical trials with the cholinergic drug RS 86 in Alzheimer's disease (AD) and senile dementia of the Alzheimer type (SDAT). Psychopharmacology (Berl). 1984;84(4):572–573. [PubMed]
  • Kaye WH, Sitaram N, Weingartner H, Ebert MH, Smallberg S, Gillin JC. Modest facilitation on memory in dementia with combined lecithin and anticholinerestase treatment. Biol Psychiatry. 1982 Feb;17(2):275–280. [PubMed]
  • Drachman DA, Glosser G, Fleming P, Longenecker G. Memory decline in the aged: treatment with lecithin and physostigmine. Neurology. 1982 Sep;32(9):944–950. [PubMed]
  • Wettstein A. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease. Ann Neurol. 1983 Feb;13(2):210–212. [PubMed]
  • Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1985 Aug;48(8):736–742. [PubMed]
  • Crook T. Clinical drug trials in Alzheimer's disease. Ann N Y Acad Sci. 1985;444:428–436. [PubMed]
  • Rada RT, Kellner R. The effects of thiothixene in geriatric patients with chronic organic brain syndrome. Psychopharmacol Bull. 1976 Apr;12(2):30–32. [PubMed]
  • Salzman C, van der Kolk B. Psychotropic drug prescriptions for elderly patients in a general hospital. J Am Geriatr Soc. 1980 Jan;28(1):18–22. [PubMed]
  • Tewfik GI, Jain VK, Harcup M, Magowan S. Effectiveness of various tranquilisers in the management of senile restlessness. Gerontol Clin (Basel). 1970;12(6):351–359. [PubMed]
  • Covington JS. Alleviating agitation, apprehension, and related symptoms in geriatric patients: A double-blind comparison of a phenothiazine and a benzodiazepien. South Med J. 1975 Jun;68(6):719–724. [PubMed]
  • Wells CE. Pseudodementia. Am J Psychiatry. 1979 Jul;136(7):895–900. [PubMed]
  • Gerner R, Estabrook W, Steuer J, Jarvik L. Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study. J Clin Psychiatry. 1980 Jun;41(6):216–220. [PubMed]
  • Passeri M, Cucinotta D, de Mello M, Storchi G, Roncucci R, Bizière K. Minaprine for senile dementia. Lancet. 1985 Apr 6;1(8432):824–824. [PubMed]
  • Bergman I, Bråne G, Gottfries CG, Jostell KG, Karlsson I, Svennerholm L. Alaproclate: a pharmacokinetic and biochemical study in patients with dementia of Alzheimer type. Psychopharmacology (Berl). 1983;80(3):279–283. [PubMed]
  • Dehlin O, Hedenrud B, Jansson P, Nörgård J. A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia. Acta Psychiatr Scand. 1985 Feb;71(2):190–196. [PubMed]
  • Reisberg B, Ferris SH, Anand R, Mir P, Geibel V, De Leon MJ, Roberts E. Effects of naloxone in senile dementia: a double-blind trial. N Engl J Med. 1983 Mar 24;308(12):721–722. [PubMed]
  • Panella JJ, Jr, Blass JP. Lack of clinical benefit from naloxone in a dementia day hospital. Ann Neurol. 1984 Mar;15(3):308. [PubMed]
  • Mayeux R, Stern Y, Spanton S. Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. Neurology. 1985 Apr;35(4):453–461. [PubMed]
  • Chui HC, Teng EL, Henderson VW, Moy AC. Clinical subtypes of dementia of the Alzheimer type. Neurology. 1985 Nov;35(11):1544–1550. [PubMed]
  • Go RC, Todorov AB, Elston RC, Constantinidis J. The malignancy of dementias. Ann Neurol. 1978 Jun;3(6):559–561. [PubMed]
  • Barclay LL, Zemcov A, Blass JP, Sansone J. Survival in Alzheimer's disease and vascular dementias. Neurology. 1985 Jun;35(6):834–840. [PubMed]
Articles from Postgraduate Medical Journal are provided here courtesy of
BMJ Group

PubMed articles by these authors